Ecomax, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
April 19, 2022 at 09:16 pm
Share
Ecomax, Inc. reported earnings results for the third quarter and nine months ended March 31, 2022. For the third quarter, the company reported net loss was USD 0.024675 million compared to USD 0.047132 million a year ago. Basic loss per share from continuing operations was USD 0.01.
For the nine months, net loss was USD 0.074527 million compared to USD 0.057658 million a year ago. Basic loss per share from continuing operations was USD 0.03.
Ecomax, Inc. is engaged in selling and distributing Rocitin NMN products to customers in the Territory. Rocitin NMN is a nutritional supplement manufactured by Pharmazeutische Fabrik Evers GmbH & Co. KG, a German company. Each bottle contains 60 capsules, 10080 mg of NMN. NMN, as β-Nicotinamide Mononucleotide exists in some fruits, vegetables, and poultry. It is a molecule naturally occurring in all life forms and can be transformed into a significant coenzyme NAD+ within cells, which is important to human metabolism. Its research, including Nicotinamide mononucleotide (NMN) as an anti-aging health product has shown that NAD+ levels in the body will decrease with age, and that exogenous supplementation of NMN enhances NAD+ levels and thus the function of human cells. In addition, NMN also helps to repair broken DNA, regulate the stability of DNA and cell death, and improve neurodegenerative and metabolic conditions.
ECOMAX, INC. 
